Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas

Bookmark and Share
Published: 15 Apr 2019
Views: 688
Rating:
Save
Prof Shoba Navai - Baylor College of Medicine, Houston, USA

Prof Shoba Navai speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from a study looking at lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas.

She explains that the study succeeded in safely doing this with very limited toxicities seen and no cardiac toxicities which can be seen in other HER-2 directed therapies.

Prof Navai reports that the addition of lymphodepletion did help improve CAR T cell expansion in the blood and that there are early signs that endogenous immunity may be engaged when administrating the CAR T cells.

Read more about this research here.